PsiOxus banks first milestone for BMS-backed cancer therapy

The $15 million payment from BMS follows the first trial of PsiOxus' "armed" oncolytic virus.

U.K. biotech PsiOxus Therapeutics has a green light for trials of its cancer-killing virus therapy for solid tumors, sparking a $15 million milestone payment from development partner Bristol-Myers Squibb.

BMS bought into the program a year ago with a $50 million upfront payment to secure rights to NG-348, an "armed" oncolytic virus, plus a pledge for milestones that could add another $900 million-plus to the tally if development goes according to plan.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Unlike regular oncolytic viruses, PsiOxus has developed a way to use them as a vehicle to deliver genes, potentially expanding the potency and flexibility of the approach.

John Beadle - CEO PsiOxus
John Beadle

The latest biobucks installment for the Oxford-based company—one of this year’s Fierce15 picks—has been activated by regulatory approval to start human clinical trials of NG-348—the first time that one of PsiOxus’ systemically delivered, intravenous anticancer gene therapy candidates has reached that stage of development, said John Beadle, M.D., the firm’s CEO, in a statement.

NG-348 virus uses PsiOxus’ tumor-specific immuno-gene therapy (T-SIGn) platform to arm the virus with two additional immuno-therapeutic transgenes. The idea is that the virus replicates within cancer cells and not within normal tissue, causing an inflammatory response that encourages lymphocytes to collect and attack the tumor.

Arming the virus with could add another level of activity, and in the case of NG-348 the additional sequences code for human CD80 and an antibody fragment specific for the T-cell receptor CD3 protein, both of which are designed to encourage a stronger immune response. PsiOxus has also discussed incorporating sequences coding therapeutic antibodies such as anti-PD-L1 and anti-CTLA4.

The clinical trial of the viral therapy will be conducted by BMS, according to PsiOxus. The two companies have also been collaborating on an ‘unarmed’ variant of the oncolytic virus—called enadenotucirev—since July 2016. That project has already passed phase 2 trials and in a phase 1/2 study in ovarian cancer. The virus can be administered intravenously, unlike oncolytic virus pioneer Imlygic (talimogene laherparepvec) from Amgen which needs to be administered directly into tumors.

There had been speculation that privately-held PsiOxus may be tempted to file an initial public offering this year, but as yet there is no news on those plans and the company has suggested it has a number of other partnerships in its sights that could postpone an IPO until 2019.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Everlywell’s sales of at-home diagnostic tests, including one kit for COVID-19, are projected to quadruple this year—and investors have taken notice.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.